Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Executive Appointments and Promotions

Pharma POOL
Aaron D. Berg
Mark A. Glickman

Oscient Names VPs to Head Key Growth Functions

Oscient Pharmaceuticals, Waltham, Mass., has appointed two senior leaders with extensive cardiovascular experience. Aaron D. Berg has been named VP of marketing and Mark A. Glickman, VP of sales. Oscient is a commercial-stage pharmaceutical company marketing two FDA-approved products with its national primary-care salesforce. Mr. Berg served as VP of marketing at Kos, and held concurrent responsibility as VP, sales, for the Eastern division leading up to the company’s acquisition by Abbott. He received a B.S. in marketing from the University of Maryland. Mr. Glickman joins Oscient from Bayer Healthcare’s Diabetes Care Division, where he was VP of sales. Mr. Glickman received his MBA from New York University and a B.A. in political science from the State University of New York. Jerzy Gruhn Martin Soeters Novo Nordisk Appoints New Leader of North American Business Novo Nordisk, Princeton, N.J., a diabetes-focused pharmaceutical company, has appointed Jerzy Gruhn as president of Novo Nordisk Inc., the company’s U.S. affiliate, and senior VP of Novo Nordisk North America. Mr. Gruhn is currently VP of the Eastern Europe region. The appointment takes effect on Jan. 1, 2008, when Mr. Gruhn will replace Martin Soeters, who takes up the position as senior VP European region, overseeing the company’s operations in 35 countries. Mr. Soeters has more than 27 years experience in Novo Nordisk in executive management, sales, and marketing. M. Fabiana Lacerca Mylan Appoints Senior VP and Chief Compliance Officer Mylan, Canonsburg, Pa., has appointed M. Fabiana Lacerca as senior VP and chief compliance officer. Mylan Laboratories develops, licenses, manufactures, markets, and distributes generic and proprietary products. Ms. Lacerca joins Mylan from Bristol-Myers Squibb where she was director of compliance for Latin America, Canada, and Puerto Rico. She earned a master of law from UCLA, a specialization in international environmental law from the Universidad de Buenos Aires, and a bachelor of law from the Universidad de Buenos Aires. Dr. Keith Wilson Takeda San Diego Names President and Chief Scientific Officer Takeda San Diego has named Keith Wilson, Ph.D., as president and chief scientific officer. Dr. Wilson is responsible for overseeing all activities related to Takeda San Diego, Takeda Pharmaceutical’s U.S.-based drug discovery company. Previously, Dr. Wilson served dual roles as VP of structural biology and VP of business development at Takeda San Diego. Dr. Wilson has formal training in protein X-ray crystallography, and he has a doctorate in physics from the University of Oregon and a bachelor’s in physics from Colby College, where he graduated magna cum laude. Biotech POOL Robert S. Radie Prestwick Strengthens Management Team Prestwick Pharmaceuticals, Washington, D.C., a privately held biotechnology company, has added Robert S. Radie to its senior management team as executive VP and chief business officer. Prestwick manages a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington’s disease, Parkinson’s disease, restless legs syndrome, schizophrenia, autism, Alzheimer’s disease, and sleep apnea. Mr. Radie is responsible for Prestwick’s commercial operations and business development activities that support its portfolio of drugs in development. He joins Prestwick from Morphotek, where he was VP of project management and chief business officer, and helped lead the successful acquisition of Morphotek by Eisai earlier this year. Biopharmaceutical POOL Dr. Steven R. Deitcher Dr. S. Michael Imperiale Hana Biosciences Appoints Senior Staff Hana Biosciences, South San Francisco, Calif., a biopharmaceutical company focused on advancing cancer care, has appointed Steven R. Deitcher, M.D., as president and CEO. Dr. Deitcher was formerly the company’s executive VP of development and chief medical officer. Before joining Hana in May 2007, Dr. Deitcher served as VP and chief medical scientist at Nuvelo. Dr. Deitcher earned his B.S. and M.D. in the honors program in medical education at Northwestern University Medical School. Hana also has appointed S. Michael Imperiale Jr., M.D., as VP, clinical research and operations. Dr. Imperiale’s experience in the life-sciences industry includes clinical strategy and program management — most recently at Nuvelo as senior director of medical sciences. He earned a doctor of medicine from Hahnemann University School of Medicine and a bachelor of arts in psychology from Villanova University. Anita Graham Shire Appoints Chief Administrative Officer Specialty biopharmaceutical company Shire, Wayne, Pa., has named Anita Graham chief administrative officer and executive VP of corporate business services. Ms. Graham is responsible for leading the corporate business services group, which consists of human resources, IT, finance operations, global procurement services, corporate communications, global facilities, and real estate management. Ms. Graham has been with Shire since January 2004, joining as executive VP of human resources. Andrew R. de Guttadauro Vical Names VP, Corporate Development Vical has appointed Andrew R. de Guttadauro as VP, corporate development. Vical, San Diego, researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Mr. de Guttadauro is responsible for product commercialization, including hands-on contributions to the successful launch and market expansion of multiple products. Before joining Vical, Mr. de Guttadauro was senior director of strategy at Biogen Idec. He earned a bachelor of science in engineering from the United States Military Academy at West Point. Dr. John L. Knopf Acceleron Pharma Appoints CEO Acceleron Pharma, Cambridge, Mass., a privately held biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, has named John L. Knopf, Ph.D., as CEO. Dr. Knopf, a founder of Acceleron, has served as the executive VP of corporate development, and recently, as president. He received his Ph.D. from SUNY Buffalo and his B.S. from SUNY Stonybrook. Malvina Laudicina Cadence Names VP of Regulatory Affairs and Quality Assurance Malvina Laudicina has joined Cadence Pharmaceutical’s management team as VP, regulatory affairs and quality assurance. Cadence, San Diego, is a biopharmaceutical company focused on in-licensing, developing, and commercializing proprietary product candidates. Ms. Laudicina leads the regulatory and quality assurance activities for the company’s two ongoing Phase III clinical development programs: intravenous acetaminophen for the treatment of acute pain and fever and Omigard for the prevention of catheter related infections. Ms. Laudicina joins Cadence from Pfizer where she was most recently involved in safety and risk management activities at the company’s La Jolla, Calif., site. She received her B.S. in chemistry from Pedro Henriquez Urena University, Santo Domingo, and her M.S. in chemistry from West Virginia University. Mark Reisenauer Micromet Appoints Senior VP and Chief Commercial Officer Micromet, Bethesda, Md., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation, and autoimmune diseases, has appointed Mark Reisenauer as senior VP and chief commercial officer. Mr. Reisenauer joins Micromet from Abbott, where he was the divisional VP and general manager of the neuroscience franchise. He holds a B.A. in political science from the University of Wisconsin. Dr. Margaret Uprichard Epix Adds Senior VP, Regulatory Affairs and Quality Biopharmaceutical company Epix, Lexington, Mass., has appointed Margaret Uprichard, Pharm.D., as senior VP, regulatory affairs and quality. Dr. Uprichard is responsible for leading all regulatory affairs activities for the company, including developing and maintaining effective regulatory strategies for Epix’s four lead product candidates, which are currently in clinical studies. Dr. Uprichard joins Epix from Point Therapeutics, where she most recently served as senior VP, chief development officer, and was responsible for leading the company’s drug development activities. Dr. Uprichard received her doctoral degree from the University of Michigan and continues to hold an academic appointment as clinical assistant professor of pharmacy. Dr. Robert F. Venteicher Affymax Names VP, Technical Operations Robert F. Venteicher, Ph.D., has joined Affymax, Palo Alto, Calif., as VP, technical operations. Affymax is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Dr. Venteicher oversees manufacturing and process development, quality and facility operations. Dr. Venteicher joined Affymax from Elan Pharmaceuticals, where he held a number of positions, most recently as VP, R&D quality and compliance. He received his B.S. in chemistry from Iowa State University and his Ph.D. in chemistry from Pennsylvania State University. Dr. Steve Worland Anadys Appoints President and CEO Anadys Pharmaceuticals, San Diego, which is committed to the development and commercialization of novel medicines for the treatment of hepatitis C virus (HCV) infection and cancer, has promoted Steve Worland, Ph.D., to president and CEO. Dr. Worland joined Anadys in March 2001 as chief scientific officer. Most recently, he served as president, pharmaceuticals, at the company. He received his B.S. in biological chemistry from the University of Michigan and his Ph.D. in chemistry from the University of California, Berkeley. Specialty POOL Dr. Lex Adjei Ventaira Appoints VP, R&D Specialty pharma company Ventaira, Columbus, Ohio, has appointed Lex Adjei, Ph.D., as VP, research and development. Most recently, Dr. Adjei served as the VP of R&D with Kos Pharmaceuticals, where he was responsible for formulation development and device support for the company’s inhaled asthma and diabetes franchises. Dr. Adjei received his Ph.D. and M.S. degrees in pharmaceutical science and a B.S. in pharmacy from The University of Texas at Austin. Dr. David Blum BDSI Names VP of Medical Affairs and Clinical Research Specialty pharmaceutical company BioDelivery Sciences International (BDSI), Morrisville, N.C., has appoined David Blum, M.D., as VP of medical affairs and clinical research. Dr. Blum is responsible for the design, conduct, analysis, and reporting of all clinical research studies required to support additional claims for the company’s Phase III Bema Fentanyl product and the development of other products in the company’s portfolio. Dr. Blum, 51, joins BDSI from GlaxoSmithKline, where he was the medical director in its neuroscience medical development department. Dr. Blum is a board certified neurologist who received his master’s in biology from the University of California, Los Angeles, and his M.D. from the University of California, San Diego. He completed his specialty training in neurology and epilepsy at the UCLA Neuropsychiatric Institute. Carl Pelzel Dr. Craig R. Smith Depomed Names Senior Staff Specialty pharmaceutical company Depomed, Menlo Park, Calif., has appointed Carl A. Pelzel as president and CEO. Mr. Pelzel, 56, has been Depomed’s executive VP and chief operating officer since 2005. Mr. Pelzel has a B.A. from Hartwick College and attended the University of Paris for two years in a premed program. Craig R. Smith, M.D., has been appointed chairman of the board of directors. Emerging POOL Dr. Jeffrey W. Sherman IDM Pharma Names Chief Medical Officer and Senior VP of R&D IDM Pharma, Irvine, Calif., has appointed Jeffrey W. Sherman, M.D., F.A.C.P., chief medical officer and senior VP of R&D. IDM Pharma is focused on the development of innovative cancer products. Dr. Sherman leads the regulatory and clinical strategy for mifamurtide (L-MTP-PE) and the development of the company’s pipeline. He joins IDM Pharma from Takeda Global Research & Development Center, a subsidiary of Takeda Pharmaceutical, where he served as VP of clinical science. Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. Agency POOL Béatrice Benoit Joseph P. Riley Jr. Susan Wingeron Nexus Promotes Staff Nexus Communications, North Wales, Pa., has promoted three employees. Béatrice Benoit has been named director, client services; Joseph P. Riley Jr., becomes editorial director, and Susan Wingeron has been named director, client services. Nexus provides strategic activities for pharmaceutical and biotechnology companies. Before her promotion, Ms. Benoit was a senior program director at Nexus. Mr. Riley has been promoted from associate editorial director. He continues to provide editorial oversight while managing the trafficking of editorial projects and developing standard operating procedures. Ms. Wingeron was a senior program director. Together with Ms. Benoit, she is responsible for strategic and tactical growth at Nexus. Danielle Bertrand Erin Bittner Julio Cantre Jessica Carlson Nicole Foderaro Monique M. Greer Julie Normart Brooke Shenkin Becky Soja Adrienne Turner WeissComm Partners Makes 10 New Hires WeissComm Partners, San Francisco, an independent communications agency focused on the healthcare industry, has made several new hires. The new hires include Danielle Bertrand, who joins as an associate, managing product and corporate communications activities for clients through various stages of commercial and pipeline development. Before joining WeissComm, Ms. Bertrand worked at Fleishman-Hillard. She has a B.A. from the University of Virginia. Erin Bittner, also an associate, joins WeissComm from The Reynolds Group. She has a B.A. in English with high honors from the University of Georgia and an M.S. in educational psychology from Georgia State University. Julio Candre has been named associate, bringing with him valuable government experience from working in the Healthcare Bureau of the Office of the Attorney General of the State of New York. He received his Juris Doctor from Brooklyn Law School, where he specialized in healthcare law and policy studies. Joining as an associate, Jessica Carlson brings a broad range of healthcare experience. Previously, she was with Fleishman-Hillard International Communications. Ms. Carlson has a B.A. in journalism and mass communications from Iowa State University. Nicole Foderaro has been named senior associate, joining the company from Nuvelo, where she was director of corporate communications and investor relations. She has a bachelor’s degree from the University of California, San Diego. Monique M. Greer takes the role of senior associate and works closely with company management to establish an integrated approach to communications. Ms. Greer was director of corporate communications at Dendreon before joining WeissComm. Julie Normart has been named associate, media specialist. She was formerly a news producer for a variety of television and radio stations throughout California. Ms. Normart has a B.A. in broadcast journalism from California State University, Fresno. Brooke Shenkin joins WeissComm as an associate from Euro RSCG Life PR. She has a B.A. in public relations from the University of Florida. Becky Soja, named associate, is a key resource in the development and implementation of product launches and branding, FDA approvals, and clinical trial recruitment programs, for a variety of therapeutic areas, including diabetes, oncology, orphan, and cardiovascular disease. She has a B.A. in public relations from East Carolina University. Adrienne Turner has been named associate, joining WeissComm from Visual Resource. She has a B.A. in geography/environmental studies from UCLA. Darin Cass David Diaz Colin Gildea Cole Gray Julie Justison Kim Panozzo Dean Yannias Williams-Labadie Promotes and Appoints Full-service healthcare agency Williams-Labadie, Chicago, a Publicis Healthcare Communications Group company, has made three promotions and four new hires. Darin Cass joins Williams-Labadie as interactive developer. Mr. Cass is responsible for the development of interactive Web content and the creation of flash animations. Previously, he served as flash designer/technical illustrator with Upchurch and Associates. David Diaz has been promoted to account supervisor. Colin Gildea was promoted to senior interactive developer. Previously, Mr. Gildea was interactive developer at Williams-Labadie. Cole Gray joins Williams-Labadie as account service manager. Mr. Gray was previously client relations manager for Penton Media. Julie Justison has been hired as art director. Before joining Williams-Labadie, Ms. Justison was the art director for Today’s Chicago Woman magazine. Kim Panozzo was promoted to account service manager. Dean Yannias has joined Williams-Labadie as senior copywriter. Mary Ann Chaffee Spectrum Science Communications Appoints Senior VP/Managing Director, Public Affairs and Health Policy Spectrum Science Communications, Washington, D.C., a health-only communications practice, has hired Mary Ann Chaffee as senior VP/managing director, public affairs and health policy. Ms. Chaffee is charged with leading Spectrum’s public affairs staff in forecasting and navigating long-term and short-term implications of health policy for its client base. She joins Spectrum after three years as VP at the Glover Park Group, where she advised companies, organizations, coalitions, and issue campaigns on policy and integrated communications strategies. Ms. Chaffee has a master of public administration degree from Harvard University’s John F. Kennedy School of Government. She also serves on the Sabin Vaccine Institute’s Board of Trustees and the Center for Infectious Disease Research’s Board of Advisors. Nick Childs Grey New York Appoints Content Developer Grey New York has appointed Nick Childs, 38, an award-winning filmmaker, as executive VP, director of content development. Grey New York is the flagship and largest office of Grey, a unit of Grey Group. Mr. Childs oversees a new, integrated content development department that encompasses broadcast, print, promotional, and digital production, and placement of original brand content. As president of Cascade Media, he has overseen the creation and production of brand, product, sales, and communications projects in every media format. Mr. Childs graduated with a B.A. in English and fiction writing from Colby College and received an M.F.A. from New York University. Laura Fusco Brendan Ward Grey Healthcare Group Hires Grey Healthcare Group (GHG), New York, has made two key hires: Laura Fusco joins the company as executive VP, director of client services, and Brendan Ward joins as executive VP, executive creative director. Ms. Fusco manages GHG new business initiatives, as well as developing systems to improve client responsiveness globally across all accounts and companies. She oversees and integrates online and offline capabilities, strengthens GHG’s medical and strategic services, and helps drive the oncology and specialty businesses. Before joining GHG, Ms. Fusco spent more than 10 years at Omnicom, most recently as managing partner, director of client services at DDB Rx. Mr. Ward creates multichannel marketing programs that educate and engage viewers, and help drive product sales. In addition, he manages the U.S. creative department, setting policy and priorities. Previously at GHG, Mr. Ward led the U.S. and worldwide campaigns for Exubera, Lexapro, and Boehringer Ingelheim’s HIV franchise, Viramune and Aptivus. Jennifer Kirchherr HealthEd Appoints Senior Staff Member HealthEd, Clark, N.J., a developer of patient education programs for pharmaceutical and healthcare marketers, has appointed Jennifer Kirchherr as senior account executive, supporting interactive media development of tailored patient education programs. Before joining HealthEd, Ms. Kirchherr was manager of online trade marketing at Oxygen Media. Ms. Kirchherr holds a bachelor of science in animal science from the University of New Hampshire and a master of professional studies from the Interactive Telecommunications Program at New York University, Tisch School for the arts. Karen Kuhlman amos MedPoint Names Director of Operations and Account Services MedPoint Communications, Evanston, Ill., a provider of communications and eMedia services to the biopharmaceutical industry, has promoted Karen Kuhlman Amos to director of clinical operations and account services. Ms. Kuhlman Amos is responsible for the strategic management and tactical implementation of MedPoint’s clinical research services as well as the supervision of the company’s project and account services teams serving this area. She joined MedPoint in 2006 and previously served as an account manager and business development executive. She holds a bachelor of arts in English and journalism from the University of Missouri. Ann Moravick Ketchum Hires Director, Global Healthcare and Brand Advocacy Global communications agency Ketchum, New York, has appointed Ann Moravick as executive VP and director, global healthcare and brand advocacy. Ms. Moravick is responsible for the practice’s strategic direction, business development, and acquisition of talent. She spearheads the global reach of the agency’s healthcare practice. Ms. Moravick previously served as the U.S. CEO of Publicis Consultants PR. Norm Phillips CommonHealth Selects Director of Strategic Planning CommonHealth, Parsippany, N.J., a WPP company and healthcare-communications network, has named Norm Phillips as executive VP, director of strategic planning. Mr. Phillips coordinates the identification of CommonHealth’s current client needs and connects them with the additional resources and services available throughout the CommonHealth organization. Before joining CommonHealth, he was a managing partner and senior VP, strategic planning at Impact Communications. Kari Seymour Vox Medica Training and Development Group Names VP Vox Medica, Philadelphia, an independent healthcare communications company, has added to its senior staff in the training and development group with the promotion of Kari Seymour to VP, healthcare training and development group. Ms. Seymour has served as senior director, program development manager, and senior training specialist. As VP, she offers her expertise in management as well as her knowledge of new business development and client service. She holds a master of education in elementary education from West Chester University and a bachelor of science in accounting from Villanova University. Marisa Sharkey JFK Communications Hires VP JFK Communications, Princeton, N.J., a healthcare public relations firm, has hired Marisa Sharkey, APR, as VP. Ms. Sharkey is responsible for a diverse mix of client services, including oncology product public relations, media relations, media training, financial communications, employee communications, online communications, and patient advocacy relations. She oversees and manages key pharmaceutical and biotechnology accounts, including Eisai Oncology and Cytogen. Before joining JFK Communications, Ms. Sharkey was director of marketing and public relations at Graduate Hospital in Philadelphia. She holds a bachelor’s in communications and a master’s in public relations, both from Rowan University in New Jersey. John Smith Fleishman-Hillard Taps Healthcare Communications Veteran to Lead Practice Public relations firm Fleishman-Hillard, Boston, part of the Omnicom Group, has appointed John Smith as senior VP and head of its Boston healthcare practice. Mr. Smith provides strategic counsel to clients in the medical technology, biotechnology, and therapeutic sectors, and continues to grow the firm’s business with leading life-sciences companies and within the broader healthcare community. He comes to Fleishman-Hillard from Manning Selvage & Lee (MS&L), where he was senior VP and director of healthcare, leading new-business efforts and overseeing several accounts. Mr. Smith holds a bachelor of arts in English from Hobart College and a master of business administration from Northeastern University. Paul Velardi Euro RSCG Life Broadens X2 Expertise Healthcare communications network Euro RSCG Life, New York, has hired Paul Velardi as president of Euro RSCG Life x2. Mr. Velardi comes to Euro RSCG Life x2 from boost inc., where he was founder and president. Consulting POOL Dr. Marc Andersen Dr. Jeffrey Wilson Aptuit Consulting Adds New Hires Aptuit has hired Marc Andersen, Ph.D., as associate, CMC practice, and Jeffrey Wilson, Ph.D., as managing director, CMC practice. Aptuit, Lexington, Mass., is an independent, global pharmaceutical, medical device, and intellectual property consultancy. Dr. Andersen has 15 years of experience in the discovery and development of small molecule active pharmaceutical ingredients from large pharma and the CRO industries. Before joining Aptuit, he was director of pharmaceutical sciences at Beckloff Associates. Dr. Andersen earned his Ph.D. at Philipps University. Dr. Wilson leads the small molecule CMC practice area for Aptuit Consulting. He is a pharmaceutical industry veteran with much small molecule chemistry, manufacturing, and control experience. Before joining Aptuit, he served as VP of pharmaceutical operations at Vertex Pharmaceuticals. Dr. Wilson earned his B.S. in chemistry at the University of New Hampshire and his Ph.D. at Duke University. J. Kevin Moran IRG Appoints Chief Operating Officer The Investor Relations Group, New York, which offers a full-service corporate communications program, has appointed Vice Admiral J. Kevin Moran, United States Navy, retired, as chief operating officer. Vice Admiral Moran recently retired from the United States Navy after a very distinguished and successful 32-year career. Vice Admiral Moran holds a bachelor of science degree in oceanography/physics from the United States Naval Academy and a master of arts degree in international relations and strategic studies from the Naval War College. He was also selected by the Navy to attend, and went on to complete, the Advanced Management Program at Harvard Business School. CRO POOL Carol Adiletto WCC Appoints Senior VP, Clinical Operations and Regulatory Affairs WorldCare Clinical (WCC), Cambridge, Mass., has appointed Carol Adiletto as senior VP of clinical operations and regulatory affairs. WCC is an imaging CRO for clinical trials for the pharmaceutical, biotechnology, and medical-device industries. Ms. Adiletto is responsible for the management of all clinical and regulatory activities, as well as the further development of WCC’s regulatory strategy. Before joining WCC, Ms. Adiletto served as VP of worldwide clinical and regulatory affairs at Pluromed and Inverness Medical Innovations. Ms. Adiletto holds an M.S. in medical laboratory science with a clinical chemistry specialization and a B.S. in medical laboratory science from Northeastern University. Dr. Honggang Bi Hani S. Zaki Covance Adds Senior Staff Covance, Princeton, N.J., a global drug development services company, has appointed Honggang Bi, Ph.D., corporate VP and general manager for Covance, China. Dr. Honggang Bi leads all Covance business activities in China and represents the organization with Chinese regulatory and government officials. Dr. Bi joins Covance from Frontage Laboratories in Malvern, Pa., where as CEO he established Frontage Laboratories in Shanghai in 2006. Dr. Bi received his Ph.D. in chemistry and drug metabolism from McGill University and holds a master of science in pharmaceutical analysis from the Institute of Materia Medica at the Chinese Academy of Medical Sciences, and a bachelor of pharmacy from the School of Pharmacy at Zhejiang University in Hangzhou. Covance has appointed Hani S. Zaki as VP and general manager of its Periapproval Services. Mr. Zaki is responsible for managing large research studies on the use of pharmaceuticals in real world clinical practice. Before joining Covance, Mr. Zaki was with PharmaNet where, as VP of business development, he led global efforts to build its Phase IIIb and Phase IV research business. Mr. Zaki holds an MBA in pharmaceutical marketing from St. Joseph’s University, an MPH in epidemiology from Tulane University’s School of Public Health and Tropical Medicine, and a B.A. in microbiology from Rutgers University. Dr. Christopher Gregory Dr. Rajagopalan Srinivasan Clinsys Announces Key Hires Therapeutically focused CRO Clinsys Clinical Research, Berkeley Heights, N.J., has hired Christopher Gregory, Ph.D., as scientific affairs-director and Rajagopalan Srinivasan, Ph.D., as VP, global biostatistics. Dr. Gregory serves as a senior scientific advisor for the clinical project teams. Before joining Clinsys, he was VP, research for Voyager Pharmaceutical. Dr. Gregory earned his doctorate in anatomy at Ohio State University and a bachelor of science in biology at Concord College. Dr. Srinivasan leads the global biostatistics service at Clinsys. He has more than 25 years of experience in biostatistics with regulated drug industry and medical research, including 10 years working at the FDA. Dr. Srinivasan received his B.Sc. (honors), M.A., and M. Phil. degrees in statistics from the University of Madras in India, his master’s in biostatistics from Florida State University, and his doctorate in biostatistics from the University of Georgia. Melissa Jones Premier Research Appoints VP, International Business Development Melissa Jones has joined Premier Research Group as VP, international business development. Premier Research, Philadelphia, is a solutions-driven CRO. Ms. Jones is responsible for leading the international business development group. Ms. Jones previously held a senior business development position within Kendle International. She has a B.Sc. honors degree in biology from the University of Portsmouth. Dr. Susan C. Stansfield PRA International Adds Senior Staff PRA International, Reston, Va., a leading CRO, has appointed Susan C. Stansfield, Ph.D., as executive VP. Dr. Stansfield is responsible for product registration activities in Europe, Africa, and the Asia-Pacific. Dr. Stansfield has more than 20 years of experience in the clinical research industry managing world-class CROs. She joins PRA International from Pharmaceutical Product Development, where she most recently served as senior VP, project management and clinical operations, Europe. Dr. Stansfield has a B.Sc. in physiology and biochemistry from Nottingham University and a Ph.D. in neuropharmacology from Reading University, both in the United Kingdom. Dr. Hugo Stephenson Quintiles Names Head of iGuard Drug Safety Service Quintiles has named Hugo Stephenson, M.D., as president of iGuard. Quintiles, Research Triangle Park, N.C., provides a broad range of professional services in drug development, financial partnering, and commercialization for the biotechnology and healthcare industries. Dr. Stephenson leads the company’s new service that offers personalized safety information and alerts to patients on the prescription drugs they are taking. Before his appointment to iGuard, Dr. Stephenson had been senior VP of Quintiles’ strategic research and safety services, a position he held since joining the company in 2003. He was the founder of Health Research Solutions, an Australian strategic research service provider acquired by Quintiles in 2002. Medical-Education POOL Dr. Filippo Cavalieri Elyse Grusky HealthMatters Makes Staff Changes Medical communications company HealthMatters Communications, New York, has appointed Filippo Cavalieri, Ph.D., as director of scientific content in the scientific communications department. Dr. Cavalieri most recently was at Global Edge. Elyse Grusky has been hired as VP, director of editorial operations and leads the scientific communications department. Ms. Grusky has been at Adelphi for the past year as the director of client services. Dr. Marco P. Cicero Vemco MedEd Appoints Director, Scientific Affairs Vemco MedEd, Bridgewater, N.J., a medical communications company, has hired Marco P. Cicero, Ph.D., as director of scientific affairs. Dr. Cicero has broad experience in the development and creation of promotional and continuing medical education programs as well as extensive expertise in medical writing and publi

Posted in:

Post a Comment

You must be logged in to post a Comment.